[Impact of a quality improvement plan on the validation of drug prescriptions on the safety of the hospitalised patient]. / Impacto de un plan de mejora de calidad en la validación de la prescripción de fármacos sobre la seguridad de los pacientes hospitalizados.

BACKGROUND AND OBJECTIVES: Medication errors are the most common adverse events in healthcare. Pharmaceutical validation (PV) seeks to reduce them. The aims of this study were to assess the impact of the introduction of an automated tool for the validation (VPAT) of the high clinical relevance drugs prescription (HCRD) over time of pharmaceutical intervention (PI), and to quantify the number of medication errors detected before and after its implementation. MATERIAL AND METHODS: A two phase retrospective-observational single centre study was designed. A pre-intervention phase (Pre-P): PV of beds with Unit Dose Dispensing (October 2015 - February 2016), was followed by a post-intervention phase (Post-P): PV using a VPAT of HCRD in hospital patients (October 2016 - February 2017). HCRD were selected from the list of high-risk drugs of Institute for Safe Medication Practices. The data was obtained from the PI record (Access®) and the computerised prescription. The variables collected were: age and gender of the patients included, data of drugs prescription, and time to PI. RESULTS: A total of 477 PI were analysed in 404 patients, with a mean age of 65.9±19.5 years (53.22% women). The mean time up to PI was 25.6±24.72h in the Pre-P, and 18.87±20.44h in the Post-P (P=0.01). In Pre-P, 106 PI were performed (35.85% prevention of adverse reactions) compared to 371 PI (39.62% medication reconciliation) in Post-P. CONCLUSIONS: The VPAT enabled a greater number of medication errors to be detected and intervened in hospitalised patients, with a significantly reduced time to PI.

Comparison of the traditional pharmaceutical validation method versus an assisted pharmaceutical validation in hospitalized patients.

OBJECTIVE: To analyze pharmaceutical interventions that have been carried out with the support of an automated system for validation of treatments vs. the traditional method without computer support. METHOD: The automated program, ALTOMEDICAMENTOS® version 0, has 925 052 data with information regarding approximately 20 000 medicines, analyzing doses, administration routes, number of days with such a treatment, dosing in renal and liver failure, interactions control, similar drugs, and enteral medicines. During eight days, in four different hospitals (high complexity with over 1 000 beds, 400-bed intermediate, geriatric and monographic), the same patients and treatments were analyzed using both systems. RESULTS: 3,490 patients were analyzed, with 42 155 different treatments. 238 interventions were performed using the traditional system (interventions 0.56% / possible interventions) vs. 580 (1.38%) with the automated one. Very significant pharmaceutical interventions were 0.14% vs. 0.46%; significant was 0.38% vs. 0.90%; non-significant was 0.05% vs. 0.01%, respectively. If both systems are simultaneously used, interventions are performed in 1.85% vs. 0.56% with just the traditional system. Using only the traditional model, 30.5% of the possible interventions are detected, whereas without manual review and only the automated one, 84% of the possible interventions are detected. CONCLUSIONS: The automated system increases pharmaceutical interventions between 2.43 to 3.64 times. According to the results of this study the traditional validation system needs to be revised relying on automated systems. The automated program works correctly in different hospitals.

Objetivo: Analizar las intervenciones farmacéuticas realizadas con el apoyo de un sistema automático de validación de tratamientos vs. el método tradicional sin apoyo informático. Metodos: El programa automatizado, ALTOMEDICAMENTOS ® version 0, cuenta con 925.052 celdas con información de aproximadamente 20.000 medicamentos, analizando dosis, vías de administración, días de tratamiento, dosificación en insuficiencia renal y hepática, control de interacciones, de medicamentos semejantes y de medicamentos por vía enteral. Durante ocho días distribuidos en cuatro hospitales diferentes (alta complejidad con más de 1.000 camas, intermedio de 400 camas, geriátrico y monográfico), los mismos pacientes y tratamientos se analizaron mediante los dos sistemas. Resultados: Se han analizado 3.490 pacientes diferentes con 42.155 tratamientos. Por el sistema tradicional se han realizado 238 intervenciones (0,56% intervenciones/posibles intervenciones) vs. 580 (1,38%) con el automatizado. Las intervenciones farmacéuticas muy significativas fueron 0,14 vs. 0,46%, las significativas 0,38 vs. 0,90%, las no significativas 0,05 vs. 0,01%. Las intervenciones fueron del 1,85% al utilizar los dos sistemas vs. 0.56% usando solo el sistema tradicional. El sistema tradicional detectó el 30,5% de las posibles intervenciones, sin embargo con el sistema automático se detectaron el 84% de dichas intervenciones. Conclusiones: La automatización multiplica entre 2,43 a 3,64 veces las intervenciones farmacéuticas. En base a los resultados de este estudio el sistema tradicional de validación debería ser modificado, apoyándose en sistemas automatizados. El programa automático funciona en diferentes hospitales.

Asociación entre indicadores de proceso medidos sobre historia electrónica y resultados intermedios en salud, en pacientes con diabetes / Relationship between process indicators measured using electronic records and intermediate health outcomes in patients with diabetes

Objetivo. Determinar, en diabetes, si la medición sobre historia electrónica de cada indicador de proceso del SERMAS se asocia a resultados intermedios en salud. Método. Estudio descriptivo transversal efectuado en el Área 1 de AP Madrid.en el año 2010. Los participantes fueron pacientes con diabetes (n = 16.652). Variables independientes: indicadores institucionales de proceso (cartera de servicios) y dependientes. Resultados intermedios: cifras controladas de HbG, TA, LDL, tabaco y peso; detección de complicaciones. Potencialmente confusoras: edad y sexo, tipo y tiempo de evolución, comorbilidad, fármacos y variables del profesional. Resultados. El 55,9% (IC 95%: 55,1-56,7%) tenía cifras controladas de HbG. El registro de los siguientes indicadores de proceso se asoció con un aumento de la probabilidad de alcanzar resultados intermedios: revisión de antecedentes familiares, personales, estilo de vida, adherencia, tratamiento, medición de HbG, peso, TA, consejo sobre tabaco, ECG, índice tobillo-brazo, creatinina y fondo de ojo. El rango de OR fue desde 1,15 (IC 95%: 1,01-1,32) a 2,05 (IC 95%: 1,76-2,39). En otros criterios no se encontró asociación: clasificación DM, medición de glucemia, revisión del plan de cuidados, medición de IMC, LDL y microalbuminuria. Conclusiones. En diabetes se encontró asociación entre los indicadores de proceso del Sermas, medidos sobre historia electrónica, y un aumento del 20-50% de la probabilidad de alcanzar resultados intermedios en salud (con excepciones). Parece recomendable mantener la medición de proceso y resultado, incorporar la medición de otros resultados intermedios, incorporar otras intervenciones de impacto, priorizar las mejoras de actividad o de registro en criterios de proceso de baja realización y alto impacto y modificar los indicadores sin asociación con resultados(AU)

Objective. To study relationship between institutional process indicators (measured using electronic records) and intermediate outcomes of patients with diabetes. Method. Cross-sectional epidemiological study. Setting Primary care health district 1. Madrid. 2010. Patients: all patients with diabetes; n = 16.652. Main measures variables. Independent. Institutional process indicators. Dependent. Intermediate outcomes: GHb, BP, LDL, tobacco and weight within target limits and detected complications. Confounding. Age, gender, type and years for DM, co-morbidity, drugs and professional variables. Results. GHb of 55,9% (SE 0,4) of patients was within target limits. Bivariate analysis and multivariate logistic regression showed that the recording of some process indicators was associated with an increase in the probability to achieve targets in intermediate outcomes: reviewing personal and family history, lifestyle and drug therapy, creatinine, GHb, BP and weight measurement, smoking advice, EKG, ankle-arm index, and eye examination. OR were from 1,15 (CI95%:1,01-1,32) to 2,05 (CI95%:1,76-2,39). Relationship among other indicators and higher probability to achieve targets was not found: classification, reviewing care plan, glucose, BMI, LDL and microalbuminury measurement. Conclusions. In diabetes, a lot of institutional process indicators measured on electronic records was associated with increase of probability to achieve targets in intermediate outcomes. It suggests to maintain process and outcome measurement, to include other outcomes, to include other interventions, to prioritize improvements in process indicators that show low performance and high impact and to keep out or to change process indicators that relationship was not found(AU)

[Relationship between process indicators measured using electronic records and intermediate health outcomes in patients with diabetes]. / Asociación entre indicadores de proceso medidos sobre historia electrónica y resultados intermedios en salud, en pacientes con diabetes.

OBJECTIVE: To study relationship between institutional process indicators (measured using electronic records) and intermediate outcomes of patients with diabetes. METHOD: Cross-sectional epidemiological study. Setting Primary care health district 1. Madrid. 2010. PATIENTS: all patients with diabetes; n = 16.652. Main measures variables. Independent. Institutional process indicators. Dependent. Intermediate outcomes: GHb, BP, LDL, tobacco and weight within target limits and detected complications. Confounding. Age, gender, type and years for DM, co-morbidity, drugs and professional variables. RESULTS: GHb of 55.9% (SE 0,4) of patients was within target limits. Bivariate analysis and multivariate logistic regression showed that the recording of some process indicators was associated with an increase in the probability to achieve targets in intermediate outcomes: reviewing personal and family history, lifestyle and drug therapy, creatinine, GHb, BP and weight measurement, smoking advice, EKG, ankle-arm index, and eye examination. OR were from 1,15 (CI 95%: 1.01-1.32) to 2.05 (CI 95%: 1.76-2.39). Relationship among other indicators and higher probability to achieve targets was not found: classification, reviewing care plan, glucose, BMI, LDL and microalbuminury measurement. CONCLUSIONS: In diabetes, a lot of institutional process indicators measured on electronic records was associated with increase of probability to achieve targets in intermediate outcomes. It suggests to maintain process and outcome measurement, to include other outcomes, to include other interventions, to prioritize improvements in process indicators that show low performance and high impact and to keep out or to change process indicators that relationship was not found.

Revisión de las reacciones de hipersensibilidad a antineoplásicos / Review of hypersensitivity reactions to antineoplastic agents

Objetivo Revisar las características y el manejo de las reacciones de hipersensibilidad causadas por agentes antineoplásicos. Método Se realizó una búsqueda bibliográfica en las bases de datos Pubmed y EMBASE de los últimos 10 años. Resultados Casi todos los quimioterápicos tienen potencial para causar una reacción de hipersensibilidad, pero determinados grupos han sido asociados con un mayor riesgo, como los derivados del platino, los taxanos, las asparraginasas, los anticuerpos monoclonales y las epipodofilotoxinas. Las manifestaciones clínicas de estas reacciones son variables e impredecibles incluyendo síntomas cutáneos, respiratorios, cardiacos y gastrointestinales. El mecanismo asociado con su desarrollo aún no se conoce en su totalidad. El diagnóstico se basa en los signos y síntomas que desarrolle el paciente y en la realización de pruebas cutáneas. El manejo de los pacientes que sufran una reacción de hipersensibilidad a un quimioterápico variará según el grado de severidad de la reacción, de la necesidad de continuar con el tratamiento y de las alternativas terapéuticas disponibles. Conclusiones Al producirse un incremento progresivo en la utilización de los agentes quimioterápicos, se puede esperar un aumento de la incidencia de las reacciones de hipersensibilidad. Los protocolos de desensibilización destacan como una alternativa que nos van a permitir reintroducir en la terapia del paciente el agente causal de la reacción de hipersensibilidad. Su utilización debe valorarse individualmente sopesando los beneficios y los riesgos (AU)

Objective To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. Method We conducted a search in the Pubmed and EMBASE databases for the last 10 years. Results Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients’ signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. Conclusions Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients’ therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits (AU)

Review of hypersensitivity reactions to antineoplastic agents.

OBJECTIVE: To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. METHOD: We conducted a search in the Pubmed and EMBASE databases for the last 10 years. RESULTS: Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients' signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. CONCLUSIONS: Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients' therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits.

Invaginación intestinal en el adulto / Intussusception in adults

La invaginación intestinal es una causa poco frecuente de dolor abdominal en adultos. Ocurre en menos del 1% de obstrucción intestinal de delgado. En adultos la mayoría de los casos son el resultado de una lesión intestinal; la invaginación idiopática es extremadamente rara. Presentamos un caso de obstrucción intestinal diagnosticado mediante tomografía computadorizada de invaginación de intestino delgado secundaria a un tumor. Se discute la etiología, diagnóstico y tratamiento de la invaginación intestinal del adulto (AU)

Intussusception is a rare cause of abdominal pain in adults. It occurs in less than 1% of all cases of adult small bowel obstruction. In adult population, most cases are the result of some type of intestinal lesion; idiopathic intussusceptions are an extremely rare occurrence in adults. This report describes one case of intestinal obstruction caused by an intussusception diagnosed by computed tomography(CT) scan. This report discusses the etiology, diagnosis, and treatment of adult intususcepción (AU)

Diagnóstico precoz del síndrome coronario agudo en los Servicios de Urgencias. Papel de la h- FABP / Early diagnosis of acute coronary syndrome in Urgency Units. Role of h-FABP

No disponible

[Iron deficiency dyserythropoiesis in patients with chronic gastrointestinal and gynecologic hemorrhages. Study of 39 cases]. / Diseritropoyesis ferropénica en pacientes con hemorragias crónicas gastrointestinales y ginecológicas. Estudio de 39 casos.

A defect of haemoglobin synthesis is the classically recognized mechanism affecting the erythron functionalism in chronic iron deficiency. The poor erythroblastic bone-marrow response, plus a number of dyserythropoietic nuclear features, have led to think of an impairment of the cell cycle of erythroblasts in iron-lack anaemia. The aim of the present work was to study such hypothesis, not proven so far. Ten subjects with normal haemopoiesis and 39 patients with iron-lack anaemia of different aetiologies (namely, 19 with digestive tract bleeding, 16 with gynaecological bleeding, and 4 with haemorrhages on other locations) were included in a previously reported protocol. The scheme of such protocol consisted of: 1) bone-marrow erythroblast quantification; 2) analysis of their maturation gradient; 3) erythroblast mitotic index; 4) measure of the mitotic time in bone-marrow culture; 5) tritiated-thymidine incorporation to short-term bone-marrow culture and quantification of the erythroblastic labelling index. To these were added the degree of nuclear dyserythropoiesis according to Hill and Lewis, and the reticulocyte production index. The following mean values were found in the control group: erythroblasts, 25.5 (+/- 3.63) %; E1-E4, 47.66 (+/- 3.09) %; IDN, 0.67 (+/- 0.27); MI, 2.82 (+/- 0.66) %; MT, 1.05 (+/- 0.15 hr); LI, 34.88 (+/- 5.82) %. The mean values found in iron-lack anaemias were as follows: erythroblasts 39.42 (+/- 9.1) %; E1-E4, 42.25 (+/- 4.11) %; IDN, 7.77 (+/- 4.69); MT, 1.81 (+/- 0.95) hr; LI, 13.08 (+/- 6.51) %. The statistical analysis (Student's t) showed highly significant differences (p less than 0.001) in the increased IDN and decreased MI and LI in iron deficiency patients.(ABSTRACT TRUNCATED AT 250 WORDS)